Summary
Effective 04/01/2026, the GLP-1 agonist policy requires pharmacy review for new-start GLP-1 agonist prescriptions, and prior authorization is required for members with type 2 diabetes who are not treated with an oral antidiabetic agent. The criteria no longer require recent or current metformin use, or documented intolerance, FDA labeled contraindication, or hypersensitivity to metformin. Mounjaro, Ozempic, Rybelsus, and Trulicity may be considered medically necessary when a type 2 diabetes diagnosis is confirmed by lab tests such as A1C greater than or equal to 6.5%, while Byetta, Bydureon, and Victoza are considered not medically necessary as other formulary options exist.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.